Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...

"Outside of metastatic castrate-resistant prostate cancer, both NCCN and ASCO do note that an osteoclast inhibitor (at ...

Hormone therapy for prostate cancer is aimed at reducing or eliminating the amount of testosterone in your body to slow or stop prostate cancer cells from growing and multiplying.

A mainstay of prostate cancer treatment at all stages is a type of hormone therapy called androgen deprivation therapy (ADT). And, newer hormone therapies and combinations with chemotherapy can ...

Among patients with metastatic hormone-sensitive prostate cancer, the treatment combination of Nubeqa (darolutamide) and androgen deprivation therapy (ADT) has reportedly displayed positive results ...

Pedro C. Barata, MD, MSc, discusses the advantages and disadvantages of darolutamide in metastatic hormone-sensitive prostate ...

Demissei BG, Ko K, Huang A, et al. Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer. J Am Coll Cardiol CardioOnc. 2024;6(3):390-401 ...

Androgen deprivation (AD) therapy for prostate cancer is being used in an increasingly wide range of settings, such as advanced disease, loco-regional disease, as an adjunct to surgery or ...

Shahzad M, Basharat A, Mujtaba G, et al. Comparing quality of life in prostate cancer patients: continuous vs. intermittent androgen deprivation therapy—a systematic review and meta-analysis.

Background: Androgen deprivation therapy (ADT) is essential for management of advanced prostate cancer, yet it carries risks including osteoporosis and fragility fractures. Antiresorptive therapy is ...